IP Library › Granted Patent US 12,337,065
Granted Patent B2
US 12,337,065 · App. 17/817,963 · Granted Jun 24, 2025

Compositions for treating viral infections and methods for same

Inventors: Jacob Waugh (Irvine, CA); Jonah Shacknai (Santa Barbara, CA)
Assignee: ACCESS TO ADVANCED HEALTH INSTITUTE
A61K9/1647A61K31/485C07K1/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,337,065
App. No.
17/817,963
Granted
Jun 24, 2025
Kind
B2
Abstract

Compositions containing a protease inhibitor for treating viral infections and methods for treating a patient before, during, or after exposure to an infectious agent by administering such compositions are described herein.

Claims (20)

1. A method for treating a subject infected by a severe acute respiratory virus, comprising: administering to a subject in need of treatment a composition comprising a furin binding compound, wherein the furin binding compound is selected from the group consisting of polylysine, α-polylysine, and ε-polylysine, and a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein administering comprises topical administration to an eye, ear, or nose of the subject.

3. The method of claim 1 , wherein administering comprises administering an intranasal spray.

4. The method of claim 1 , wherein administering comprises administering at least once per day.

5. The method of claim 1 , whereby said administering reduces viral load in patient sputum or blood plasma by at least about 20%.

6. The method of claim 1 , whereby said administering improves time to recovery by at least about 20%.

7. The method of claim 1 , wherein the severe acute respiratory virus is SARS-CoV-2.

8. The method of claim 7 , wherein the subject is suffering from COVID-19.

9. The method of claim 8 , whereby said administering reduces long term effects of COVID-19.

10. The method of claim 1 , wherein the furin binding compound comprises about 95% (w/w) to about 5% (w/w) furin binding compound based on the total weight of the composition.

11. The method of claim 1 , wherein the composition further comprises an antiviral agent.

12. The method of claim 1 , further comprising administering an antiviral agent or an anti-inflammatory agent with the composition.

13. The method of claim 12 , wherein administering the antiviral agent or anti-inflammatory agent comprises administration simultaneously or sequentially with the composition.

14. The method of claim 12 , wherein administering the antiviral agent or anti-inflammatory agent comprises administration via oral administration or by injection.

15. The method of claim 11 , wherein the antiviral agent is acyclovir, amantadine hydrochloride, amprenavir, cytarabine, delavirdine mesylate, edoxudine, efavirenz, famciclovir, floxuridine, fomivirsen, foscarnet, ganciclovir, idoxuridine, indinavir, lamivudine, nelfinavir mesylate, nevirapine, oseltamivir phosphate, penciclovir, ribavirin, rimantadine hydrochloride, ritonavir, saquinavir, saquinavir mesylate, sorivudine, trifluridine, valaciclovir, vidarabine, kethoxal, methisazone, moroxydine, podophyllotoxin, ribavirin, rimantadine, stallimycine, statolon, tromantadine, xenozoic acid, zalcitabine, zanamivir, or combinations thereof.

16. The method of claim 1 , wherein the composition further comprises an anti-inflammatory agent.

17. The method of claim 16 , wherein the anti-inflammatory agent is hyaluronic acid, curcumin, glutathione, methotrexate, tofacitinib, 6-mercaptopurine, azathioprine sulfasalazine, mesalazine, olsalazine chloroquine/hydroxychloroquine, penicillamine, aurothiomalate, azathioprine, colchicine, corticosteroids, a beta-2 adrenoreceptor agonist, a xanthine, cromoglycate, nedocromil, ketotifen, ipratropium and oxitropium, cyclosporin, FK506, rapamycin, mycophenolate mofetil, leflunomide, a corticosteroid, a phosphodiesterase inhibitor, an adenosine agonist, an antithrombotic agent, a complement inhibitor, an adrenergic agent, TNF, IL-1, an IL-1 converting enzyme inhibitor, a T-cell signaling inhibitor, a metalloproteinase inhibitor, sulfasalazine, a 6-mercaptopurine, an angiotensin converting enzyme inhibitor, a soluble cytokine receptor, an anti-inflammatory celecoxib, folic acid, cytokine, hydroxychloroquine sulfate, rofecoxib, etanercept, infliximab, adalimumab, certolizumab, tocilizumab, abatacept, naproxen, valdecoxib, sulfasalazine, methylprednisolone, meloxicam, methylprednisolone acetate, gold sodium thiomalate, triamcinolone acetonide, propoxyphene napsylate/apap, folate, nabumetone, diclofenac, piroxicam, etodolac, diclofenac sodium, oxaprozin, oxycodone HCl, hydrocodone bitartrate/apap, diclofenac sodium/misoprostol, fentanyl, anakinra, tramadol HCL, salsalate, sulindac, cyanocobalamin/fa/pyridoxine, acetaminophen, alendronate sodium, prednisolone, cortisone, betamethasone, morphine sulfate, lidocaine hydrochloride, indomethacin, glucosamine sulf/chondroitin, amitriptyline HCl, sulfadiazine, oxycodone HCV acetaminophen, olopatadine HCl misoprostol, omeprazole, cyclophosphamide, rituximab, IL-1 TRAP, MRA, CTLA4-IG, IL-18 BP, anti-IL-12, Anti-ILIS, BIRB-796, SCI0-469, VX-702, AMG-548, VX-740, Roflumilast, IC-485, CDC-801, SIPI agonists, a PKC family inhibitor, Mesopram, budesonide; epidermal growth factor; a corticosteroid; cyclosporin, sulfasalazine; an aminosalicylate; 6-mercaptopurine; azathioprine; metronidazole; a lipoxygenase inhibitor; mesalamine; olsalazine; balsalazide; an antioxidant; a thromboxane inhibitor; an IL-1 receptor antagonist; an anti-IL-1 monoclonal antibody; an anti-IL-6 monoclonal antibody; a growth factor; an elastase inhibitor; a pyridinyl-imidazole compound; an antibody to or antagonist of other human cytokines or growth factors; a cell surface molecule; methotrexate; cyclosporine; FK506; rapamycin; mycophenolate mofetil; leflunomide; a corticosteroid; a phosphodiesterase inhibitor; an adenosine agonist; an antithrombotic agent; a complement inhibitor; an adrenergic agent; an agent that interferes with signaling by proinflammatory cytokines, TNF 5, or IL-1; an IL-1 converting enzyme inhibitor; a TNF converting enzyme inhibitor; a T-cell signaling inhibitor, or a kinase inhibitor; a metalloproteinase inhibitor; sulfasalazine; azathioprine; a 6-mercaptopurine; an angiotensin converting enzyme inhibitor; a soluble cytokine receptor, an anti-inflammatory cytokine, the gene encoding Cytokine-inducible SH 2 -containing protein (CISH), antibody BGB-A317, Nivolumab, or Pembrolizumab, atezolizumab, avelumab, durvalumab, ipilimumab; and combinations thereof.

18. A method for treating a subject infected by a severe acute respiratory virus, comprising: administering to a subject in need of treatment a composition comprising a furin binding compound, wherein the furin binding compound is selected from the group consisting of a peptide, a peptide analog, and a peptidomimetic.

19. The method of claim 18 , wherein the furin binding compound has a polyarginine sequence.

20. The method of claim 19 , wherein the polyarginine sequence is RKRKKR (SEQ ID NO:2), RKKR (SEQ ID NO:3), or RRRKKR (SEQ ID NO:4).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2023
From: WAUGH, JACOB; SHACKNAI, JONAH
To: TIGER DEVELOPMENT, LLC
Reel/Frame 065076/0612 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2023
From: BELMONT HOLDINGS TRUST; SETH RODNER REVOCABLE TRUST
To: ACCESS TO ADVANCED HEALTH INSTITUTE
Reel/Frame 065076/0908 →
DEED OF GIFT Recorded Aug 9, 2023
From: BELMONT HOLDINGS TRUST; SETH RODNER REVOCABLE TRUST
To: ACCESS TO ADVANCED HEALTH INSTITUTE
Reel/Frame 064546/0360 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2022
From: WAUGH, JACOB; SHACKNAI, JONAH
To: TIGER DEVELOPMENT, LLC
Reel/Frame 060738/0449 →
Continuity (4)
Continuation 17472750 · Sep 13, 2021
Continuation 17304343 · Jun 18, 2021
Provisional Application 63065754 · Aug 14, 2020
Related Publication 20220370360A1 · Nov 24, 2022
References Cited (39)
US 8022179B2 · Dake et al. · 2011 [cited by applicant]
US 10729735B1 · Newman et al. · 2020 [cited by applicant]
US 10744189B2 · Schluch et al. · 2020 [cited by applicant]
US 11433028B2 · Waugh et al. · 2022 [cited by applicant]
US 20050153841A1 · Bunt et al. · 2005 [cited by applicant]
US 20060018867A1 · Kawasaki et al. · 2006 [cited by applicant]
US 20090029924A1 · Strongin et al. · 2009 [cited by applicant]
US 20200197288A1 · Gudmundsdottir · 2020 [cited by examiner]
US 20210401751A1 · Waugh et al. · 2021 [cited by applicant]
US 20230081039A1 · Zhang et al. · 2023 [cited by applicant]
IN 307KOL2010 · 2016 [cited by applicant]
WO WO2007046781A1 · 2007 [cited by examiner]
WO 2022029577 · 2022 [cited by applicant]
WO WO2022029577A1 · 2022 [cited by applicant]
Hosoya et al (Antiviral Chemistry & Chemotherapy vol. 2 (4), pp. 243-248) (Year: 1991). [cited by examiner]
Cheng et al., “Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects”, Cell Reports, vol. 33, No. 2, Art. 108254, 18 pages (2020). [cited by applicant]
Coutard et al., “The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade”, Antiviral Res., vol. 176, No. 104742, 6 pages (2020). [cited by applicant]
Couture et al., “On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications”, Biomol. Concepts, vol. 2, No. 5, pp. 421-438 (2011) [cited by applicant]
Cramer et al., “Poly-L-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses”, ChemRxiv, Preprint, Article downloaded from https://doi.org/10.26434/chemrxiv.13072025.v1, 32 pages (2020). [cited by applicant]
Dahlen et al., “Inhibition of soluble recombinant furin by human proteinase inhibitor 8”, J. Biol. Chem., vol. 273, No. 4, pp. 1851-1854 (1998). [cited by applicant]
Farag et al., “Identification ofFDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning”, ChemRxiv, pp. 1-20 (2020). [cited by applicant]
Huijghebaert et al. “Does Trypsin Oral Spray (Viruprotect®/ColdZyme®) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union”, Int. J. Environ. Res. Pub… [cited by applicant]
International Search Report from International Application No. PCT/US2022/018379, 7 pages , Mailed Nov. 2, 2022. [cited by applicant]
Langeland et al., “Interaction of polylysine with the cellular receptor for herpes simplex virus type 1”, J. Gen. Virol., vol. 69, Pt. 6, pp. 1137-1145 (1988). [cited by applicant]
Palit et al., “Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?”, Phytomedicine, vol. 85, No. 153396, 21 pages (2021). [cited by applicant]
Paull et al., “Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro”, Antiviral Res., vol. 191, No. 105089, 8 pages (2021). [cited by applicant]
Seigfried et al., “Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases”, Oncogene, vol. 24, No. 46, pp. 6925-6935 (2005). [cited by applicant]
Stagi et al., “Effective SARS-CoV-2 antiviral activity of hyperbranched polylysine nanopolymers”, Nanoscale, Royal Society of Chemistry, vol. 13, No. 39, pp. 16465-16476 (2021). [cited by applicant]
Chen, et al., “Furin Inhibitors Black SARA-C0V-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects,” Cell Reports 33, 108254, Oct. 13, 2020, 18 pages. [cited by applicant]
Couture, et al., “On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications,” Bimol Concepts. Oct. 1, 2011;2(5): 421-438. [cited by applicant]
Siegfried, et al., “Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases,” Onogene (2005), 24, 6925-6953, 11 pages. [cited by applicant]
Dahlen, et al., “Inhibition of Soluble Recombinant Furin by Human Proteinase Inhibitor 8*,” The Journal of Biological Chemistry, vol. 273, No. 4, Issue of Jan. 23, 1998, pp. 1851-1854. [cited by applicant]
Palit, et al., “Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking; can it be a potential therapeutic option for Covid-19?”, Phytomedicine 85 (2021) 153396, 21 pages. [cited by applicant]
Huijghebaert, et al., “Does Trypsin Oral Spray (Vituprotect(R)/ColdZyme(R)) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union,” Int. J. Environ. Re… [cited by applicant]
Paull, et al., “Virucidal and antivaral activity of astrodrimer sodium against SARS-CoV-2 in vitro,” May 16, 2021, published by Eselvier B., V., 8 pages. [cited by applicant]
Langeland, “Interaction of Polylysine with the Cellular Receptor for Herpes Simplex Virus Type 1,” JJ. ge. Virol. (1988), 69, 1137-1145, 10 pages. [cited by applicant]
Coutard, et al., “The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade,” retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/labs/pmc/arti… [cited by applicant]
International Search Report and Written Opinon for related application PCT/US2022/018379 mailed Nov. 2, 2023, 33 pages. [cited by applicant]
Vienot, et al., “Effective SARS-CoV-2 antiviral activity of hyperbranched polylysine nanopolymers,” Nanoscale, vol. 13, Oct. 21, 2021, pp. 16465-16476, XP055940974. [cited by applicant]